PART TWO

The Expansion of Modern Drug Markets

Kratom did not arrive into a neutral environment. It arrived into a population that had been pharmacologically prepared — by decades of market evolution, policy failure, and opioid saturation — to receive it. To understand why kratom found the audience it did, you have to understand what that audience had already been through. And to understand that, you have to follow the markets.

Four Decades of Market Evolution

Begin in the 1970s. Cocaine trafficking expanded dramatically across the United States, moving through organized distribution networks tied to international cartels. Powdered cocaine introduced a generation to stimulant pharmacology in a way that had no real precedent in American consumer culture. The drug was expensive, and its harms — while real — were largely behavioral and cardiovascular rather than the grinding physical dependence that opioids produce.

Then, in the mid-1980s, crack cocaine arrived and changed the pharmacological calculus entirely. Crack was not simply a cheaper version of cocaine. It was a pharmacologically distinct delivery system with a shorter onset and a more intense, compressed reinforcement cycle. Its spread through urban retail markets was an early demonstration of a principle that would recur across drugs and decades: products that deliver faster, more intense reinforcement cycles spread more efficiently through market systems. The compression dynamic operates at the market level as well as the individual one. Crack displaced powder cocaine in many markets not just because it was cheaper but because the cycle it produced was tighter, more demanding, more effective at generating repeat consumption. The market selected for it.

By the 1990s, heroin had become the dominant opioid threat in many regions. Mexican trafficking organizations expanded black tar heroin production and distribution, and for the first time large numbers of Americans encountered genuine physical opioid dependence — the body-level chemistry of withdrawal, craving, and the particular desperation of opioid detox.

Then came the pharmaceutical opioid era. OxyContin launched in 1996. Over the following two decades, prescription opioids moved through medical channels and introduced opioid pharmacology to populations that had never encountered illicit drug markets at all. Millions of people who had no prior relationship with heroin developed physical opioid dependence through a doctor’s office and a pharmacy. The opioid-exposed population expanded across demographics that earlier epidemics had largely bypassed: suburban, rural, middle-class, elderly.

As regulatory pressure tightened on prescription opioids in the early 2010s, illicit markets evolved with the speed that markets always demonstrate when demand persists and supply is constrained. Fentanyl began displacing heroin — higher potency, easier clandestine manufacturing, dramatically narrowed safety margins. The market had been moving toward faster, more intense cycles for forty years. Fentanyl was the logical endpoint of that trajectory: cocaine became crack, cigarettes became nicotine salts, coffee became caffeine shots, and heroin became fentanyl. In each case the system moved toward a faster signal, a shorter cycle, more repetition. This is not coincidence. It is the selection pressure of competitive markets applied to pharmacologically active products. It is, in clinical terms, interval compression operating at a civilizational scale.

The Kindled Market

Across all of these transitions, something important was accumulating: a large and growing population that was familiar, at a body level, with opioid pharmacology. Not familiar in the sense of having read about it — familiar in the sense of having lived through withdrawal, understood the cycle of relief and depletion, and developed nervous systems that had adapted, in lasting ways, to opioid receptor stimulation.

The term kindling comes from neurology, where it describes the way repeated stimulation lowers the threshold for future responses. A brain that has been exposed to opioids carries that history forward in measurable and durable ways. A population with widespread opioid exposure is, in this sense, a kindled market — one whose collective neurological threshold for opioid-like compounds has been systematically lowered over decades. This reframes kratom’s emergence not as a drug trend but as a market entering an already primed population. It helps explain why certain substances spread quickly: they are not creating demand from nothing. They are meeting demand that history already created.

I understand this not only from two decades of front-line work but as someone who lived it. I came of age in Louisiana during an era when heroin carried sentences severe enough — decades at hard labor for meaningful quantities — that the drug was genuinely difficult to find outside certain corridors. The market, as it existed then, contained the damage through scarcity in ways that no treatment program managed to replicate. What changed was not human neurology. What changed was access. And when access changed, everything else followed.

When kratom began appearing on smoke shop shelves in the 2010s, it did not need to recruit a naive population. It entered a landscape shaped by forty years of opioid market evolution, arriving precisely when pharmaceutical opioids were being restricted and heroin markets were transitioning to fentanyl. For a significant portion of that kindled population, kratom’s partial opioid agonism was not a side effect. It was the product. Understanding how that agonism behaves differently across product formats — powder versus extract — is part of what the 7-OH vs. kratom comparison is designed to address.

The Consumer Who Wasn’t Looking

But the kindled market is only part of the story, and letting it become the whole narrative would miss something important. A significant portion of the people who developed dependence on modern kratom products had no prior opioid history at all. They were not self-medicating withdrawal. They were not seeking a legal substitute for heroin, or a safer alternative to fentanyl. They bought a supplement. They followed the label. They used it for energy, or chronic pain, or anxiety — the way people use any retail wellness product — and found themselves weeks or months later in what can only be described as compressed cycle opioid dependence when they tried to stop.

This population complicates the story in a productive way. The kindled market explains one pathway into dependence. The supplement consumer represents another: a person with no pharmacological history, no framework for understanding what was happening in their body, no obvious place to turn when the product that was supposed to help them became something they could not stop taking. The market was primed by history. But history was not required. The product system was sufficient on its own.

The Infrastructure Converges

At the same time, the retail environment was expanding in ways that made distribution frictionless. Cannabis legalization had normalized regulated retail drug markets and established a commercial infrastructure — dispensaries, branded products, consumer-facing retail — that made plant-derived psychoactive products feel ordinary. Smoke shops and specialty retailers, looking for revenue as tobacco markets contracted, broadened their inventories to include botanical extracts and psychoactive supplements. Online vendors developed global supply chains that could move products across international borders faster than any regulatory response could track. The full scope of how this infrastructure shaped what consumers were actually buying is covered in the Retail Pharmacology overview.

The product existed. The distribution infrastructure existed. The kindled population existed, and beside it a new population of ordinary consumers with no prior history and no warning. What retail pharmacology required was for these elements to converge — and by the mid-2010s, they had. If you’re trying to understand where you or someone you know fits into this pattern, the How the Kinetic Exit Works is a good starting point.

Previous: Part One — From Plant Medicine to Alkaloid Products

Next: Part Three — Compressed-Cycle Opioid Dependence and the Tightening Loop

Back to Series Overview Retail Pharmacology

John Leonard is the founder of Pivot Protocols and a recovery program leader with 23 years of front-line experience. The frameworks on this site were developed through direct observation, pattern recognition, and grounding in published pharmacological research. He is not a clinician or medical provider.